|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Optimizing hepatitis C virus treatment through pharmacist interventions: Identification and management of drug-drug interactions显示文摘AIM To quantify drug-drug-interactions(DDIs) encountered in patients prescribed hepatitis C virus(HCV) treatment, the interventions made, and the time spent in this process.METHODS As standard of care, a clinical pharmacist screened for DDIs in patients prescribed direct acting antiviral(DAA) HCV treatment between November 2013 and July 2015 at the University of Colorado Hepatology Clinic. HCV regimens prescribed included ledipasvir/sofosbuvir(LDV/SOF), paritaprevir/ritonavir/ombitasvir/dasabuvir(OBV/PTV/r + DSV), simeprevir/sofosbuvir (SIM/SOF), and sofosbuvir/ribavirin (SOF/RBV). This retrospective analysis reviewed the work completed by the clinical pharmacist in order to measure the aims identified for the study. The number and type of DDIs identified were summarized with descriptive statistics.RESULTS Six hundred and sixty four patients(83.4% Caucasian, 57% male, average 56.7 years old) were identified; 369 for LDV/SOF, 48 for OBV/PTV/r + DSV, 114 for SIM/SOF, and 133 for SOF/RBV. Fifty-one point five per cent of patients were cirrhotic. Overall, 5217 medications were reviewed (7.86 medications per patient) and 781 interactions identified (1.18 interactions per patient). The number of interactions were fewest for SOF/RBV (0.17 interactions per patient) and highest for OBV/PTV/r + DSV (2.48 interactions per patient). LDV/SOF and SIM/SOF had similar number of interactions (1.28 and 1.48 interactions per patient, respectively). Gastric acid modifiers and vitamin/herbal supplements commonly caused interactions with LDV/SOF. Hypertensive agents, analgesics, and psychiatric medications frequently caused interactions with OBV/PTV/r + DSV and SIM/SOF. To manage these interactions, the pharmacists most often recommended discontinuing the medication (28.9%), increasing monitoring for toxicities (24.1%), or separating administration times (18.2%). The pharmacist chart review for each patient usually took approximately 30 min, with additional time for more complex patients. CONCLUSION DDIs are common with HCV medications and management can require medication adjustments and increased monitoring. An interdisciplinary team including a clinical pharmacist can optimize patient care. | Jacob A Langness Matthew Nguyen Amanda Wieland Gregory T Everson Jennifer J Kiser | 2017 | World Journal of Gastroenterology2017，23，9： | 5 |
| 2 | To surcharge or not to surcharge: An empirical investigation of ATM pricing 显示文摘 | Hannah T H Kiser E K Prager R A | 2003 | The Review of Economics and Statistics2003，85，4： | 1 |
| 3 | Plastic flow and fracture of a particulate metal matrix composite 显示文摘 | KISER M T ZOK F W WILKINSON D S | 1996 | Acta Mater1996，44，12： | 1 |
| 4 | Proton pump inhibitors and histamine-2 receptor antagonists in the intensive care setting:focus on therapeutic and adverse events显示文摘 | MacLaren R Kassel L E Kiser T H | 2015 | Expert Opin Drug Saf2015，14，2： | 1 |
| 5 | Plastic flow and fracture of a particulate metal matrix composite显示文摘 | Kiser M T Zok F W Wilkinson D S | 1996 | Acta Mater1996，44，9： | 1 |
| 6 | Measurement of paclitaxel in biological matrices: high-throughput liquid chromatographic-tandem mass spectrometric quantification of paclitaxel and metabolites in human and dog plasrna显示文摘 | Alexander M S Kiser M M Culley T | 2003 | J Chromatogr B Analyt Technol Biomed Life Sei2003，785，2： | 1 |
| 7 | Use of a motorized bicycle exer- cise trainer to normalize frequency-dependent habituation of the H-re- flex in spinal cord injury 显示文摘 | Kiser TS Reese NB Maresh T | 2005 | J Spinal Cord Med2005，28，3： | 1 |
| 8 | Influence of milking frequency onproductive and reproductive efficiencies of dairy cows显示文摘 | Amos H E Kiser T Loewenstein M | 1985 | Dairy Sci1985，68，3： | 1 |
| 9 | MUC1 inhibits cell proliferation by a β-catenin-dependent mechanism 显示文摘 | Lillehoja EP Lu W Kiser T | 2007 | Biochim Biophys Acta2007，1773，7： | 1 |
| 10 | Titanium nanomaterial removal and release from wastewater treatment plants显示文摘 | Kiser M Westerhoff P Benn T | 2009 | Environmental Science&Technology2009，43，17： | 1 |
| 11 | Plastic flow and fracture of a particulate metal matrix composite显示文摘 | Kiser M T Zok F W and Wilkinson D S | 1996 | Acta Mater1996，44，12： | 1 |
| 12 | Titanium nanomateri- al removal and release from wastewater treatment plants 显示文摘 | Kiser M A Westerhoff P Benn T | 2009 | Environmental science & technology2009，43，17： | 1 |
| 13 | Plastic Flow and Fracture of a Particulate Metal Matrix Composite显示文摘 | Kiser M T Zok F W Wilkinson D S | 1996 | Acta Materialia1996，44，9： | 1 |
| 14 | 显示文摘 | Kiser M T Zok F W Wilkinson D S | 1996 | Acta Mater1996，44，： | 1 |
| 15 | Levofloxacin pharmacokinetics and pharmacodynamics in patients with severe burn injury显示文摘 | Kiser T H Hoody D W Obritsch M D | 2006 | Antimicrob Agents Chemother2006，50，6： | 1 |
| 16 | Plastic flow and fracture of a particulate metal matrix composite显示文摘 | Kiser M T Zok F W SWilkinson D | 1996 | Acta Materialia1996，44，9： | 1 |
| 17 | Titanium nanomaterial removal and release from wastewater treatment plants 显示文摘 | KISER M A WESTERHOFF P BENN T | 2009 | Environmental Science and Technology2009，43，17： | 1 |
| 18 | Titanium nanomaterial removal and release from wastewater treatment plants显示文摘 | Kiser M A Westerhoff P Benn T | | 0，，17： | 1 |
| 19 | An expectation confirmation perspective of medical tourism显示文摘 | Chou S Y Kiser A I T Rodriguez E L | 2012 | Journal of Service Science Research2012，4，2： | 1 |
| 20 | Plastic Flow and Fracture of a Particulate Metal Matrix Composite显示文摘 | Kiser M T Zok F W Wilkinson D S | 1996 | Acta Mater1996，44，12： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员